News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
190,329 Results
Type
Article (7818)
Company Profile (15)
Press Release (182496)
Section
Business (66285)
Career Advice (394)
Deals (12332)
Drug Delivery (17)
Drug Development (28116)
Employer Resources (42)
FDA (4444)
Job Trends (4774)
News (108639)
Policy (8173)
Tag
Academia (468)
Africa (166)
Alabama (18)
Allergies (18)
Alliances (7793)
Alzheimer's disease (369)
Antibody-drug conjugate (ADC) (25)
Approvals (4439)
Arizona (27)
Asia (11826)
Australia (1704)
Bankruptcy (86)
Best Places to Work (4089)
Biosimilars (17)
C2C Services and Suppliers (17326)
California (543)
Canada (293)
Cancer (132)
Career advice (328)
Cell therapy (33)
China (33)
Clinical research (22967)
Collaboration (29)
Colorado (23)
Connecticut (19)
COVID-19 (702)
Data (78)
Diabetes (21)
Diagnostics (1744)
Earnings (49993)
Employer resources (34)
Europe (26541)
Events (34525)
Executive appointments (16)
FDA (4507)
Florida (65)
Funding (29)
Gene therapy (16)
Georgia (15)
GLP-1 (179)
Government (1074)
Healthcare (5719)
Hotbed/Location (134530)
Illinois (50)
Indiana (57)
Infectious disease (709)
Inflammatory bowel disease (20)
Interviews (79)
IPO (7379)
Job creations (721)
Job search strategy (289)
Kansas (18)
Layoffs (119)
Legal (1471)
Lung cancer (32)
Maine (31)
Manufacturing (17)
Maryland (98)
Massachusetts (478)
Medical device (3856)
Medtech (3856)
Mergers & acquisitions (4933)
Metabolic disorders (80)
Michigan (28)
Minnesota (71)
Neuroscience (406)
New Hampshire (22)
New Jersey (204)
New York (207)
NextGen Class of 2024 (1422)
Non-profit (916)
North Carolina (187)
Northern California (279)
Obesity (47)
Opinion (36)
Patents (16)
Peanut (16)
Pennsylvania (210)
People (6105)
Phase I (6006)
Phase II (9820)
Phase III (8899)
Pipeline (85)
Postmarket research (1005)
Preclinical (2036)
Rare diseases (24)
Real estate (868)
Recruiting (22)
Regulatory (5881)
Research institute (434)
Resumes & cover letters (57)
South America (276)
Southern California (213)
Startups (589)
Texas (60)
United States (2610)
Utah (21)
Vaccines (122)
Washington State (120)
Weight loss (46)
Date
Last 7 days (163)
Last 30 days (1073)
Last 365 days (14647)
2024 (9748)
2023 (15117)
2022 (18166)
2021 (18192)
2020 (16427)
2019 (13467)
2018 (9720)
2017 (9610)
2016 (8552)
2015 (10865)
2014 (8031)
2013 (5966)
2012 (6452)
2011 (6731)
2010 (5946)
190,329 Results for "8".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
BioMidwest
DiaMedica Therapeutics Announces Closing of $11.8 Million Private Placement
DiaMedica Therapeutics Inc. today announced the closing of its previously announced $11.8 million private placement to accredited investors.
July 1, 2024
·
9 min read
Biotech Beach
GRI Bio to Present at the 8th Annual IPF Summit
GRI Bio, Inc. today announced that Vipin Kumar Chaturvedi, PhD, Chief Scientific Officer of GRI Bio, will present at the 8th Annual IPF Summit taking place August 20-22, 2024 in Boston, MA.
July 1, 2024
·
4 min read
Osteoarthritis Market Size, Trends and Companies Report | 8.4% - CAGR Growth by 2032
The global osteoarthritis market size was valued at USD 8.60 billion in 2023 and is poised to grow from USD 9.26 billion in 2024 to reach around USD 19.15 billion by 2032, at a CAGR of 8.4% during the forecast period 2023-2032.
June 27, 2024
·
13 min read
Clene Presents Preliminary Data for CNM-Au8® as a Potential Treatment for Rett Syndrome
Clene Inc. today announced it presented new, preliminary data demonstrating the potential of CNM-Au8 as a treatment for Rett Syndrome.
June 21, 2024
·
8 min read
Genetown
Bluejay Diagnostics Announces Closing of $8.75 Million Underwritten Public Offering
Bluejay Diagnostics, Inc. announced the closing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company.
June 28, 2024
·
5 min read
Deals
Bluejay Diagnostics Announces Pricing of $8.75 Million Underwritten Public Offering
Bluejay Diagnostics, Inc. today announced the pricing of a firm commitment underwritten public offering with gross proceeds to the Company expected to be approximately $8.75 million, before deducting underwriting discounts and other estimated expenses payable by the Company.
June 27, 2024
·
5 min read
Business
Freyja Healthcare Secures $8M in New Funding and Appoints Tracy MacNeal as Independent Board Director
Freyja Healthcare, an early-stage medical device company specializing in women’s health, has secured $8 million in new funding.
June 25, 2024
·
3 min read
Business
Viatris to Report Second Quarter 2024 Financial Results on August 8, 2024
Viatris Inc. (NASDAQ: VTRS) will report its second quarter 2024 financial results on Thursday, August 8, 2024, before the open of the U.S. financial markets.
June 7, 2024
·
1 min read
BioMidwest
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced it will be hosting a virtual meeting of its stockholders at 1pm ET on Monday, July 8th, 2024.
June 20, 2024
·
5 min read
Business
Roche Inks Potential $1.8B Deal With Ascidian to Develop RNA Exon Therapies
Ascidian Therapeutics will receive $42 million upfront from Roche, and up to $1.8 billion in milestone payments and royalties, to discover RNA exon editing candidates for neurological diseases.
June 18, 2024
·
2 min read
·
Tyler Patchen
1 of 19,033
Next
